Provider review
WeightlessRx review
Will not restart your titration from week one if you switch to it.
And publishes the committed and month-to-month rates together on every card.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
WeightlessRx
$174/mo month-to-month semaglutide, less on a three-month plan
- Vs median
- $5/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two things make this worth reading and neither is the headline figure. The first is that both rungs are published on every card, so the decision to commit or stay flexible can be made on the page rather than discovered at a checkout — and the month-to-month rate is roughly double the committed one, which is the number that actually applies if you are starting cautiously. The second is a policy most providers do not state at all: if you are already on a GLP-1 and switching, your clinician can continue you at or near your current titration level rather than restarting you from week one. Anyone who has changed providers mid-course knows what that is worth, because restarting a titration means paying for weeks of a dose you already passed through and living with the side effects again. Lock in your price for life is attached to both products, which is a stronger promise than a flat-dose one because it covers renewals as well as dose increases. Both figures are floors and no milligram appears, so the promise cannot be checked against a quantity.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You are switching providers mid-course and do not want to restart your titration
- You want both the committed and flexible rates in front of you before choosing
- You want a price locked against renewals as well as dose increases
Look elsewhere if
- You want to stay month-to-month — that rate is roughly double the headline
- You want a rate rather than a starting point
- You want a dose behind the number
What it actually costs
Price as published
★★ BOTH RUNGS ON EVERY CARD: compounded semaglutide "From $89/mo — From $174/mo month-to-month · save more on the 3-month plan" and compounded tirzepatide "From $133/mo — From $250/mo month-to-month" · so the committed figure and the no-commitment figure sit together and the size of the gap is visible without a checkout · ★ "Lock in your price for life" is attached to both, which is a stronger claim than the usual flat-dose promise because it survives dose increases AND renewals · ★★ AND THE TITRATION POLICY IS PUBLISHED: "Your clinician can continue you at or near your current titration level when clinically appropriate, so you do not have to restart from week one" — the single most useful sentence on the page for anyone switching providers mid-course · unlimited clinician messaging, titration guidance and an app are named as included · both figures are floors · no milligram is published
- Vs median
- $5/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. ★★ No low-dose product, but two things matter more here than a tier. Both rungs are published on every card, so the commit-or-not decision is made on the page rather than at a checkout. And the titration policy is stated: a switching patient is continued at or near their existing level rather than restarted from week one, which is the difference between weeks of a dose already passed and picking up where they left off. The price lock covers renewals as well as dose increases.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Included
- Labs
- Not required
- Pricing
- Flat at every dose
- Price last updated
- August 2026
What it does well
- Publishes the committed and month-to-month rates together on every card.
- States that a switching patient is not restarted from week one of titration.
- Locks the price for life, covering renewals as well as dose increases.
Pharmacy, labs and oversight
WeightlessRx does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
3 of 4 published openly
What WeightlessRx publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsOne price at every dose, so the bill is knowable before you titrate.
- Published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two things make this row worth reading and neither is the headline. The first is that both rungs are published on every card, so the commit-or-not decision can be made on the page rather than at a checkout, and the month-to-month rate is roughly double the committed one — which is the number that actually applies to anyone starting cautiously. The second is a policy most providers do not state at all: a switching patient can be continued at or near their existing titration level rather than restarted from week one. Anyone who has moved providers mid-course knows what that is worth, because restarting a titration means weeks of a dose that was already passed and a bill for each of them. Lock in your price for life is attached to both products, which is a stronger promise than a flat-dose one since it covers renewals as well as dose increases. Both figures are floors and no milligram appears, so the promise cannot be checked against a quantity.
The honest cons
The month-to-month rate is roughly double the advertised committed one.
- Both figures are floors with nothing above them published.
- No milligram appears, so the price-lock cannot be checked against a quantity.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
WeightlessRx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#369 of 373
Ordered with the companies that pay us first, and WeightlessRx is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.